Establishment Labs Holdings Inc. develops and markets medical technology for women’s health, principally breast aesthetics and reconstruction. The company’s recurring news covers Motiva implants and related minimally invasive platform activity, global product adoption, U.S. and outside-the-U.S. commercialization, and sales channels serving distributors, physicians, hospitals, and clinics.
Updates also include quarterly and annual financial results, revenue guidance, operating expense leverage, adjusted EBITDA commentary, credit-facility refinancing, leadership changes, and health care conference participation. Product and market updates commonly center on the Motiva portfolio, silicone-filled breast and body-shaping implants, and expansion across Europe, Latin America, Asia-Pacific/Middle East, and other markets.
Establishment Labs (NASDAQ: ESTA) received FDA approval to add 28 sizes to its Motiva breast implant portfolio in the United States.
The expansion covers Motiva SmoothSilk Round and SmoothSilk Ergonomix, including implants as small as 105 cc. It adds combinations of base, projection and volume across the Mini, Demi and Full profiles. Round adds 19 sizes: 10 Mini sizes ranging from 105 to 230 cc, four Demi sizes from 135 to 190 cc, and five Full sizes from 145 to 235 cc. Ergonomix adds nine sizes: three Mini sizes ranging from 105 to 140 cc, one Demi size of 135 cc, and five Full sizes from 145 to 235 cc.
The company plans commercial availability before the end of 2026. Management said the expanded range gives surgeons more choice for traditional procedures and more versatility for its minimally invasive platform.
Establishment Labs (ESTA) presented new clinical and scientific data on Breast Tissue Preservation and its Minimally Invasive Platform and announced product line extensions for its Mia and Preservé systems at the 11th World Symposium on Ergonomic Implants in Istanbul.
Data from the recently published four-part Breast Tissue Preservation Building Blocks Supplement in the Aesthetic Surgery Journal were highlighted, covering breast anatomy, tissue preservation rationale, and early- and mid-term clinical outcomes, including the first published U.S. multicenter experience with Preservé. The company said expanded Mia and Preservé sizes and supporting tools are planned, aligning with industry data showing an 11% growth in the augmentation market.
Establishment Labs (NASDAQ: ESTA) reported unaudited Q2 2026 revenue of $67.5 million, up 31.7% year over year and 12.8% sequentially, with Motiva USA revenue rising to $24.7 million. Minimally invasive revenue reached $12.1 million.
Gross profit was $47.7 million with a margin of 70.6%, up from 68.8%. Loss from operations narrowed to $4.3 million and net loss to $11.7 million, while adjusted EBITDA turned positive at $3.7 million. The company raised 2026 revenue guidance to $269–$271 million, and ended June 30, 2026 with $71.2 million in cash, a $16.5 million increase versus a year earlier.
Establishment Labs (NASDAQ: ESTA) will release its financial results for the quarter ended June 30, 2026 before the market opens on Thursday, August 6, 2026. The company will host a conference call at 8:30 AM ET, with access by phone and webcast via its investor relations website.
According to Establishment Labs, it is a global medical device company focused on women’s health in breast aesthetics and reconstruction, offering Motiva® implants and minimally invasive platforms such as Mia Femtech®, Preservé™, GEM®, Motiva Flora®, and Zensor™ RFID-based technologies.
Establishment Labs (NASDAQ: ESTA) appointed veteran healthcare executive Taylor Harris to its Board of Directors. Harris has over 25 years of experience in corporate finance, leadership, and board governance across healthcare, medical technology, and life sciences.
His background includes CEO of Cutera, CFO roles at MyoKardia, Zeltiq Aesthetics, and Thoratec, where he helped guide multiple acquisitions, including MyoKardia’s $13.1 billion sale to Bristol Myers Squibb. According to Establishment Labs, he brings specific expertise in medical aesthetics and shareholder value creation.
Establishment Labs (NASDAQ: ESTA) will join the US small-cap Russell 2000 Index when markets open on June 29, 2026, as part of the Russell indexes reconstitution.
Membership, based on inclusion in the Russell 3000 Index, also adds the stock to related growth and value indexes.
Establishment Labs (NASDAQ: ESTA) reported Q1 2026 revenue of $59.9 million, up 44.7% year-over-year, and raised full-year revenue guidance to $266.5–$268.5 million. Motiva U.S. sales were $19.6 million. Gross margin improved to 70.7% and adjusted EBITDA was $1.2 million. Cash totaled $68.1 million as of March 31, 2026.
The company increased 2026 minimally invasive guidance to exceed $35 million, expects positive adjusted EBITDA every quarter, and aims for free cash flow positivity in H2 2026.
Establishment Labs (NASDAQ: ESTA) entered a $300 million senior secured first‑lien term loan with funds managed by Oaktree Capital. The facility has a five‑year maturity, two tranches (Tranche E $265M to refinance existing indebtedness; Tranche F $35M for growth), no amortization, and a fixed rate with potential step‑down tied to leverage.
The loan refinances prior debt, preserves a first‑priority lien on substantially all assets, and is intended to extend maturity and provide working capital to support operations and strategic growth.
Establishment Labs (NASDAQ: ESTA) will report first-quarter 2026 results before market open on May 6, 2026 and host a conference call at 8:30 am ET. Dial-in and a live/archived webcast are available via the company website. The release reiterates product portfolio, ongoing IRB‑approved pivotal studies, regulatory and manufacturing credentials, and global commercial footprint.
Establishment Labs (NASDAQ: ESTA) announced it has surpassed five million Motiva devices in market across more than 100 countries, reflecting adoption since 2010. The company reported over 25% revenue growth in 2025 and cited US market entry and its minimally invasive Preservé platform as drivers of 2026 momentum.
Preservé is priced about 30% higher than standard Motiva augmentation, and the company operates two ISO13485:2024 and FDA 21 CFR 820 compliant manufacturing facilities in Costa Rica.